VERTEX PHARMACEUTICALS INC / MA (VRTX)
A+
Pipeline Grade
Financial Position (from SEC Filings)
$5,504.9M
Cash & Equivalents
$1,428.1M
Quarterly Burn Rate
$115,017M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (7 Assets)
| Drug | Phase | Indications |
|---|---|---|
|
ELEXACAFTOR, IVACAFTOR, TEZACAFTOR, IVACAFTOR
TRIKAFTA (COPACKAGED) |
APPROVED | — |
|
SUZETRIGINE
JOURNAVX |
APPROVED | — |
|
IVACAFTOR, LUMACAFTOR
ORKAMBI |
APPROVED | — |
|
DEUTIVACAFTOR, TEZACAFTOR, VANZACAFTOR CALCIUM
ALYFTREK |
APPROVED | — |
|
IVACAFTOR
KALYDECO |
APPROVED | — |
|
IVACAFTOR, IVACAFTOR, TEZACAFTOR
SYMDEKO (COPACKAGED) |
APPROVED | — |
|
TELAPREVIR
INCIVEK |
NDA | — |
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-07-16 | Phase1 Readout | — |
| 2026-09-17 | Phase3 Readout | — |
| 2026-10-30 | Phase3 Readout | — |
| 2026-11-19 | Phase1 Readout | — |
| 2026-12-30 | Phase2 Readout | — |
| 2026-12-31 | Phase3 Readout | — |
| 2027-01-25 | Phase3 Readout | — |
| 2027-02-02 | Phase2 Readout | — |
| 2027-02-26 | Phase1 Readout | — |
| 2027-03-05 | Phase1 Readout | — |
| 2027-03-12 | Phase2 Readout | — |
| 2027-03-23 | Phase1 Readout | — |
| 2027-03-25 | Phase2 Readout | — |
| 2027-04-06 | Phase3 Readout | — |
| 2027-04-06 | Phase3 Readout | — |
| 2027-05-31 | Phase3 Readout | — |
| 2027-06-06 | Phase3 Readout | — |
| 2027-06-09 | Phase3 Readout | — |
| 2027-06-30 | Phase3 Readout | — |
Active Clinical Trials (34)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT07538570 | Evaluation of Pain Treatment After Total Knee Arthroplasty | PHASE4 | Recruiting | 60 |
| NCT06747572 | Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease | OTHER | Active Not Recruiting | 401 |
| NCT07463430 | Suzetrigine for Non-Mastectomy Breast Surgery | PHASE4 | Enrolling By Invitation | 120 |
| NCT05444257 | A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy | PHASE3 | Active Not Recruiting | 822 |
| NCT05329649 | Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD) | PHASE3 | Active Not Recruiting | 13 |
| NCT04786262 | A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes | PHASE3 | Recruiting | 52 |
| NCT07231419 | Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy | PHASE3 | Recruiting | 734 |
| NCT06696443 | Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripher... | PHASE3 | Active Not Recruiting | 455 |
| NCT04208529 | A Long-term Follow-up Study in Participants Who Received CTX001 | PHASE3 | Enrolling By Invitation | 160 |
| NCT05477563 | Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia a... | PHASE3 | Recruiting | 26 |
| NCT05844449 | Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Ye... | PHASE3 | Enrolling By Invitation | 174 |
| NCT05331183 | Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508d... | PHASE3 | Active Not Recruiting | 297 |
| NCT05312879 | Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease | PHASE3 | Recruiting | 466 |
| NCT06628908 | Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy | PHASE3 | Recruiting | 1,100 |
| NCT05356195 | Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT) | PHASE3 | Active Not Recruiting | 16 |
| NCT06460506 | Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older | PHASE3 | Active Not Recruiting | 50 |
| NCT05422222 | Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age | PHASE3 | Active Not Recruiting | 210 |
| NCT06832410 | An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant | PHASE3 | Recruiting | 10 |
| NCT05791201 | A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes | PHASE2 | Active Not Recruiting | 7 |
| NCT02623972 | A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer | PHASE2 | Active Not Recruiting | 22 |
| NCT06794996 | Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With or Without Comorbidities | PHASE2 | Active Not Recruiting | 42 |
| NCT01920932 | Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage ... | PHASE2 | Active Not Recruiting | 77 |
| NCT06538116 | A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease | PHASE2 | Active Not Recruiting | 300 |
| NCT06619860 | Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy | PHASE2 | Recruiting | 300 |
| NCT06185764 | A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) | PHASE2 | Recruiting | 52 |
| NCT07161037 | Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW) | PHASE2 | Recruiting | 24 |
| NCT04339738 | Testing the Addition of Nivolumab to Chemotherapy in Treatment of Soft Tissue Sarcoma | PHASE2 | Active Not Recruiting | 90 |
| NCT06926621 | A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I | PHASE2 | Enrolling By Invitation | 44 |
| NCT07378865 | Evaluation of the Excretion of Suzetrigine Into Breast Milk in Healthy Lactating Female Participants | PHASE1 | Recruiting | 12 |
| NCT06154447 | Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis | PHASE1 | Active Not Recruiting | 165 |
| NCT07584434 | A Phase 1, First-in-human Study of VX-433 | PHASE1 | Recruiting | 118 |
| NCT07283770 | Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants | PHASE1 | Recruiting | 128 |
| NCT07437105 | Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants | PHASE1 | Recruiting | 128 |
| NCT07570069 | Effects of Efavirenz on the Pharmacokinetics of Suzetrigine in Healthy Participants | PHASE1 | Active Not Recruiting | 18 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.
FDA-Related SEC Filings
| Date | Type | Description | Link |
|---|---|---|---|
| 2026-07-07 | 8-K | VERTEX PHARMACEUTICALS INC / MA (VRTX) (CIK 0000875320) - EX-99.1 | EDGAR |